EpiCast Report: Growth Hormone Deficiency – Epidemiology Forecast to 2026

2017-06-01
Price :
Published : Jun-2017
No. of Pages : 36

EpiCast Report: Growth Hormone Deficiency – Epidemiology Forecast to 2026

Summary

GHD is an endocrine disorder characterized by the insufficient production of GH by the pituitary gland (CGF, 2003). The ICD-10 Clinical Modification (ICD-10-CM) code for GHD is E23.0. GHD is more commonly seen in children, although it can develop during adulthood. GHD can be present from birth, in which case it is known as congenital, or it can be secondary due to brain trauma and is known as acquired. The signs and symptoms of the disease can vary. Generally, a child with GHD is born with normal size at birth, but has delayed rates of bone development and bone lengthening later on. GHD in children affects growth and development.

In the 7MM, the diagnosed prevalent cases of GHD for all ages and both sexes will increase from 109,551 cases in 2016 to 112,450 cases in 2026 at an Annual Growth Rate (AGR) of 0.26%. Our epidemiologists forecast an increase in the diagnosed prevalent cases of GHD in all markets except Germany and Japan.

In 2016, the US made up about 48% of all diagnosed prevalent cases of GHD in the 7MM. In 2016, the 5EU made up approximately 40%, and Japan made up nearly 13%, of all cases of GHD in the 7MM. Our epidemiologists maintained a consistent forecast methodology across all the 7MM, which allows for comparison between each of the seven markets. Due to the limited availability of market-specific epidemiological studies available, further research is needed to better understand inter-market variations of the epidemiological parameters.

The report “EpiCast Report: Growth Hormone Deficiency – Epidemiology Forecast to 2026” provides an overview of the risk factors, comorbidities, and global trends for GHD in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed prevalent cases of GHD in children (ages 18 years and younger) and adults (ages 19 years and older) segmented by age and sex from 2016 to 2026. The diagnosed prevalent cases of GHD are further segmented into the classification of the disease (idiopathic and organic in children, and idiopathic and acquired in adults). Organic GHD in children is further segmented into congenital and acquired. GHD in adults is segmented by timing of disease onset: childhood onset GHD (COGHD) and adult onset GHD (AOGHD).

Scope

– The Growth Hormone Deficiency (GHD) EpiCast Report provides an overview of the risk factors, comorbidities, and global trends of GHD in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed prevalent cases of GHD in children (ages 18 years and younger) and adults (ages 19 years and older) segmented by age and sex. The diagnosed prevalent cases of GHD are further segmented into the classification of the disease (idiopathic and organic in children, and idiopathic and acquired in adults). Organic GHD in children is further segmented into congenital and acquired. GHD in adults is segmented by timing of disease onset: childhood onset GHD and adult onset GHD.
– The GHD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
– The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The GHD EpiCast report will allow you to –
– Develop business strategies by understanding the trends shaping and driving the global GHD market.
– Quantify patient populations in the global GHD market to improve product design, pricing, and launch plans.
– Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for GHD therapeutics in each of the markets covered.
– Identify the percentage of GHD diagnosed prevalent cases by various clinical segmentations.

Filed in: Pharmaceutical
Publisher : GlobalData
More Reports
Title Price Buy Now

Company Profile: 23andMe

Company Profile: 23andMe Summary 23andMe is a personal genomics and biotechnology company that leverages machine learning technology to provide DNA analysis services. It also offers web-based interactive tools to individuals, helping them understand their own genetics information. Scope The report provides information and insights into 23andMe, including - - Overview of the company and its product offering - Detailed insight into its business operation, technology, revenue model, geographical presence and business model - Information on partnerships, funding and awards it received - Biography of top management. Reasons to buy - Gain insights into 23andMe's business operations. - Gain insights into funding and partnerships. - Gain understanding about its technology focus and success ......
$350

Company Profile: Fitbit, Inc.

Company Profile: Fitbit, Inc. Summary Fitbit, Inc. (Fitbit) offers a range of connected health and fitness devices that monitors various health parameters like sleep duration, heart rate, BMI, calories burned, exercise routines, etc. Scope The report provides information and insights into Fitbit, Inc., including - - Overview of the company and its product offering - Detailed insight into its business operation, technology, revenue model, geographical presence and business model - Information on partnerships, funding and awards it received - Biography of top management. Reasons to buy - Gain insights into Fitbit business operations. - Gain insights into funding and partnerships. - Gain understanding about its technology focus and success factors.......
$350

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – India

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - India Summary GlobalData, the industry analysis specialist, has released its latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - India". The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in India. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure of India. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research, and in-house analysis by ......
$1995

The State of the Microbiome

The State of the Microbiome Summary GlobalData's "The State of the Microbiome", report provides an assessment of how the pharmaceutical industry perceives the state of the microbiome, including the challenges associated with developing, launching, and manufacturing microbiome therapeutics as well as where opportunity remains to invest in the microbiome space. Scope - Microbiome investment - determine level of activity and investment in the development of microbiome therapeutics by therapy area - Identify the challenges associated with - Developing microbiome therapeutics - Launching microbiome therapeutics - Manufacturing microbiome therapeutics. Reasons to buy - Develop and design your corporate strategies in the microbiome space by understanding the challenges associated with devel......
$1495

Rheumatoid Arthritis: Epidemiology Forecast to 2027

Rheumatoid Arthritis: Epidemiology Forecast to 2027 Summary Rheumatoid arthritis (RA) is an autoimmune disease characterized by inflammation of the joints, bone and cartilage erosion, and joint deformity. Additionally, the condition manifests itself in multiple joints in the body. In RA, the body's immune system attacks the lining of the joints, known as the synovial membrane, or synovium, causing an inflammatory response. The disease can lead to premature mortality, disability, and decreased quality of life. GlobalData epidemiologists used sources that provided the diagnosed incidence, diagnosed prevalence, and total prevalence of RA based on the 1987 American College of Rheumatology (ACR) criteria and International Classification of Diseases, Tenth Edition (ICD-10): M05 and M06. In 2......
$3995

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – Q3 2018

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q3 2018 Summary GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q3 2018", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q3 2018. The report portrays detailed comparative data on the number of deals and their value in the last five quarters, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides informati......
$1500

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – China

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - China Summary GlobalData, the industry analysis specialist, has released its latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - China". The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in China. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure of China. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research, and in-house analysis by ......
$1995

Burkitt Lymphoma Global Clinical Trials Review, H2, 2018

Burkitt Lymphoma Global Clinical Trials Review, H2, 2018 Summary GlobalData's clinical trial report, "Burkitt Lymphoma Global Clinical Trials Review, H2, 2018" provides an overview of Burkitt Lymphoma clinical trials scenario. This report provides top line data relating to the clinical trials on Burkitt Lymphoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials databa......
$2500

Cholangitis Global Clinical Trials Review, H2, 2018

Cholangitis Global Clinical Trials Review, H2, 2018 Summary GlobalData's clinical trial report, "Cholangitis Global Clinical Trials Review, H2, 2018" provides an overview of Cholangitis clinical trials scenario. This report provides top line data relating to the clinical trials on Cholangitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials ......
$2500

Celiac Disease Global Clinical Trials Review, H2, 2018

Celiac Disease Global Clinical Trials Review, H2, 2018 Summary GlobalData's clinical trial report, "Celiac Disease Global Clinical Trials Review, H2, 2018" provides an overview of Celiac Disease clinical trials scenario. This report provides top line data relating to the clinical trials on Celiac Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clin......
$2500
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy